fbpx

Joint Care | Intervention

Brochure

Leader Biomedical’s Joint Care Intervention portfolio offers a targeted solution for deferring osteoarthritis with Hyalosyn™ Gel. The Hyaluronic Acid (HA) injections supplement the natural human HA found in the synovial joints, and increase the shock-absorbing capacity as well as reduce pain. Additionally, this portfolio offers a solution for osteotomy with our range of OssGro® synthetic grafts promoting bone regeneration.

Please send this document to my inbox

Fields marked with * are required
LB_two runners on road

Deferring osteoarthritis

Hyalosyn™ Gel is a 1% sodium hyaluronate viscoelastic solution, manufactured by synthetic fermentation. Treatment with HA is clinically proven for osteoarthritis for over 10 years.
Supplementing the joint fluid’s natural viscosity with viscosupplementation is a proven, effective treatment to improve joint movement, increase mobility, reduce pain, and defer osteoarthritis progression.

  • Manufactured by synthetic fermentation
  • No microbiological residues
  • Suitable for intra-articular injection into all synovial joints
  • Sterile pre-filled syringe for easy injection
  • Clinically proven therapy for osteoarthritis for over 10 years

Osteotomy

Leader Biomedical’s OssGro® synthetic bone grafts are produced with MBCP Technology, a proprietary method for producing high quality synthetic bone grafts composed of 60% HA and 40% βTCP. Our OssGro® synthetic bone grafts support new bone formation promoted by the release of calcium and phosphate ions.

MBCP Technology is a sophisticated process of synthesis with several heating steps ensuring good mechanical strength with resorption rates resembling real bone, especially when used in conjunction with bone marrow or proline-rich proteins (PRPs), adding osteoinductive properties to the graft.

Advantages:

  • Regeneration
  • Porosity
  • Permeability
  • Safety
  • Availability

Please send this document to my inbox

Fields marked with * are required